- Home
- BYRN vs AVXL Comparison
BYRN vs AVXL Comparison
Compare BYRN & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BYRN
- AVXL
- Stock Information
- Founded
- BYRN 2005
- AVXL 2004
- Country
- BYRN United States
- AVXL United States
- Employees
- BYRN N/A
- AVXL N/A
- Industry
- BYRN Industrial Machinery/Components
- AVXL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BYRN Miscellaneous
- AVXL Health Care
- Exchange
- BYRN Nasdaq
- AVXL Nasdaq
- Market Cap
- BYRN 670.5M
- AVXL 710.3M
- IPO Year
- BYRN N/A
- AVXL N/A
- Fundamental
- Price
- BYRN $30.33
- AVXL $9.09
- Analyst Decision
- BYRN Strong Buy
- AVXL Strong Buy
- Analyst Count
- BYRN 2
- AVXL 2
- Target Price
- BYRN $36.00
- AVXL $44.00
- AVG Volume (30 Days)
- BYRN 463.3K
- AVXL 768.8K
- Earning Date
- BYRN 07-08-2025
- AVXL 08-05-2025
- Dividend Yield
- BYRN N/A
- AVXL N/A
- EPS Growth
- BYRN N/A
- AVXL N/A
- EPS
- BYRN 0.61
- AVXL N/A
- Revenue
- BYRN $95,292,000.00
- AVXL N/A
- Revenue This Year
- BYRN $37.49
- AVXL N/A
- Revenue Next Year
- BYRN $21.56
- AVXL N/A
- P/E Ratio
- BYRN $49.98
- AVXL N/A
- Revenue Growth
- BYRN 87.26
- AVXL N/A
- 52 Week Low
- BYRN $7.79
- AVXL $3.76
- 52 Week High
- BYRN $34.78
- AVXL $14.44
- Technical
- Relative Strength Index (RSI)
- BYRN 60.31
- AVXL 64.24
- Support Level
- BYRN $30.55
- AVXL $7.97
- Resistance Level
- BYRN $32.71
- AVXL $9.35
- Average True Range (ATR)
- BYRN 1.98
- AVXL 0.38
- MACD
- BYRN 0.08
- AVXL 0.18
- Stochastic Oscillator
- BYRN 64.26
- AVXL 86.10
About BYRN Byrna Technologies Inc.
Byrna Technologies Inc is a designer, manufacturer, retailer, and distributor of technological solutions for security situations that do not require the use of lethal force. The company generates its revenue from the United States, South Africa, Europe, South America, Asia, and Canada.
About AVXL Anavex Life Sciences Corp.
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.